Berubicin

Drug Profile

Berubicin

Alternative Names: Berubicin (B); Berubicin hydrochloride; Reata 744; RTA 744; WP744

Latest Information Update: 02 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Reata Pharmaceuticals
  • Class Anthracyclines; Antineoplastics
  • Mechanism of Action Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Brain cancer; Glioma; Neoplastic meningitis

Most Recent Events

  • 16 Apr 2008 Interim efficacy, adverse events and pharmacokinetics data from a Phase-I trial in Glioblastoma presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008) ,
  • 09 Jul 2007 Data presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2007) added to the adverse events, pharmacokinetics and Cancer therapeutic trials sections ,
  • 30 Oct 2006 Berubicin receives orphan drug status for the treatment of malignant gliomas in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top